Merck KGaA Raises Guidance as Life Science and Electronics Drive 4.1% Organic Growth
The German science and technology company beat expectations in Q2 on strength in semiconductor materials and bioprocessing, while integrating its SpringWorks acquisition and awaiting Bio-Techne deal closure.
Strong Quarter Across Core Divisions
Merck KGaA reported accelerating momentum in its second quarter, with organic sales growth reaching 4.1% and reported net sales climbing to €5.434 billion from €5.255 billion year-over-year (earnings call, 2026-08-06). The German science and technology group saw EBITDA pre margins expand 1.6 percentage points to 29.4%, prompting management to raise full-year guidance.
"Q2 was a pretty robust quarter," CEO Kai Beckmann said on the call. "Following a solid start into the year, we continue to build growth momentum in the second quarter" (earnings call, 2026-08-06).
Life Science led the performance with 8% organic growth, powered by Process Solutions, which delivered 15% organic sales growth. CFO Helene von Roeder noted the division benefited from "strong underlying demand, supported by temporarily stronger purchasing activity in APAC and new customer projects" (earnings call, 2026-08-06). However, she cautioned that "the assumption... namely a normalization of the second half of '26, does remain valid" (earnings call, 2026-08-06).
Electronics Accelerates, Healthcare Shows Mixed Results
Electronics posted its strongest performance with organic growth accelerating to 11.7% in the quarter. Semiconductor Solutions drove results with 17% organic growth, "fueled by continued demand in semi materials, driven by advanced nodes in both logic and memory" (earnings call, 2026-08-06). The performance reflects continued momentum in the semiconductor manufacturing sector, though Optronics faced headwinds from consumer electronics markets.
Healthcare presented a more complex picture, with organic sales declining 3.4% but reported sales up 2.4% thanks to a 5.4% positive portfolio effect from rare diseases (earnings call, 2026-08-06). The recently acquired rare disease portfolio from SpringWorks delivered €207 million in combined H1 sales from OGSIVEO and associated products, in line with guidance.
The division also saw "initial sales of pimicotinib following the private market launch in China" (earnings call, 2026-08-06). However, Specialty Care declined 6% organically, primarily due to Mavenclad's loss of U.S. market exclusivity and competitive pressure on Bavencio.
Bio-Techne Integration and Strategic Investments
Beckmann highlighted the June 25 signing of a definitive agreement to acquire Bio-Techne Corporation, expected to close by year-end or early 2027. Von Roeder indicated the deal would bring "immediate EBITDA premargin accretion" with run-rate cost synergies of approximately €140 million by year three (earnings call, 2026-08-06).
The company continues investing in manufacturing capacity, including a €20 million metrology and inspection site near Grenoble, France, opened in June to expand semiconductor tooling capabilities.
EPS pre increased 6.9% to €2.16 despite higher interest costs from the SpringWorks acquisition financing (earnings call, 2026-08-06). Net financial debt stood at €9.2 billion as of June 30, mainly reflecting dividend payments.
Management also flagged the upcoming implementation of IFRS 18 accounting standards in January 2027, noting simulations suggest "the deviation of past and future EBITDA pre is less than 2%" (earnings call, 2026-08-06).
According to MarginX data, the company is scheduled to present at Morgan Stanley's 14th Annual Laguna Conference on September 15, followed by the Berenberg and Goldman Sachs German Corporate Conference later that month.
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.